Lonza reports softer performance in Q1 2024

Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s

USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab

Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor

FDA grants full approval for TIVDAK to treat cervical cancer

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer

Merck 1Q 2024 sales up 9% to US$ 15.8 billion

Sales reflect continued strong growth in oncology and vaccines

GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA

Submission based on results from pivotal phase III trial showing all primary endpoints met

Croda and AAHI partner to drive innovation in vaccine development

The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development

Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer

AstraZeneca and Daiichi Sankyo’s BLA for Dato-DXd accepted in the US for treatment of breast cancer

Application based on results from the TROPION-Breast01 Phase III trial

Merck invests € 300 million in new Life Science production site in South Korea

New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics

AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer